112 related articles for article (PubMed ID: 21278437)
1. Breast cancer management: opportunities and barriers to an individualized approach.
Perez EA
Oncologist; 2011; 16 Suppl 1():20-2. PubMed ID: 21278437
[TBL] [Abstract][Full Text] [Related]
2. Too Much, Too Little, or Just Right? Obesity and Dosing of Targeted Therapies in Breast Cancer.
Cao C; Ligibel JA
J Clin Oncol; 2023 Nov; 41(33):5090-5092. PubMed ID: 37797274
[No Abstract] [Full Text] [Related]
3. Histopathological Patterns and Outcomes of Triple-Positive Versus Triple-Negative Breast Cancer: A Retrospective Study at a Tertiary Cancer Center.
Kadi MS; Alhebshi AH; Shabkah AA; Alzahrani WA; Enani GN; Samkari AA; Iskanderani O; Saleem AM; Farsi AH; Trabulsi NH
Cureus; 2023 Jul; 15(7):e42389. PubMed ID: 37621828
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D: an essential adjuvant therapeutic agent in breast cancer.
Thabet RH; Gomaa AA; Matalqah LM; Shalaby EM
J Int Med Res; 2022 Jul; 50(7):3000605221113800. PubMed ID: 35883275
[TBL] [Abstract][Full Text] [Related]
5. Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework.
de Belvis AG; Pellegrino R; Castagna C; Morsella A; Pastorino R; Boccia S
J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357121
[TBL] [Abstract][Full Text] [Related]
6.
Elian FA; Are U; Ghosh S; Nuin P; Footz T; McMullen TPW; Brindley DN; Walter MA
Breast Cancer (Dove Med Press); 2021; 13():171-188. PubMed ID: 33688250
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Wang L; Wang Y; Su B; Yu P; He J; Meng L; Xiao Q; Sun J; Zhou K; Xue Y; Tan J
Sci Rep; 2020 Oct; 10(1):16504. PubMed ID: 33020551
[TBL] [Abstract][Full Text] [Related]
8. A rapid volume of interest-based approach of radiomics analysis of breast MRI for tumor decoding and phenotyping of breast cancer.
Demircioglu A; Grueneisen J; Ingenwerth M; Hoffmann O; Pinker-Domenig K; Morris E; Haubold J; Forsting M; Nensa F; Umutlu L
PLoS One; 2020; 15(6):e0234871. PubMed ID: 32589681
[TBL] [Abstract][Full Text] [Related]
9. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis.
Sanges F; Floris M; Cossu-Rocca P; Muroni MR; Pira G; Urru SAM; Barrocu R; Gallus S; Bosetti C; D'Incalci M; Manca A; Uras MG; Medda R; Sollai E; Murgia A; Palmas D; Atzori F; Zinellu A; Cambosu F; Moi T; Ghiani M; Marras V; Santona MC; Canu L; Valle E; Sarobba MG; Onnis D; Asunis A; Cossu S; Orrù S; De Miglio MR
BMC Cancer; 2020 Jun; 20(1):491. PubMed ID: 32487046
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory Effects of Osthole on Human Breast Cancer Cell Progression via Induction of Cell Cycle Arrest, Mitochondrial Dysfunction, and ER Stress.
Park W; Park S; Song G; Lim W
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31731635
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for persistent and late radiation complications in breast cancer survivors.
Fekrmandi F; Panzarella T; Dinniwell RE; Helou J; Levin W
Clin Transl Oncol; 2020 Mar; 22(3):360-369. PubMed ID: 31123988
[TBL] [Abstract][Full Text] [Related]
12. Stromal Infiltration of Tumor-Associated Macrophages Conferring Poor Prognosis of Patients with Basal-Like Breast Carcinoma.
Yang M; Li Z; Ren M; Li S; Zhang L; Zhang X; Liu F
J Cancer; 2018; 9(13):2308-2316. PubMed ID: 30026826
[No Abstract] [Full Text] [Related]
13. Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells.
Lucantoni F; Lindner AU; O'Donovan N; Düssmann H; Prehn JHM
Cell Death Dis; 2018 Jan; 9(2):42. PubMed ID: 29352235
[TBL] [Abstract][Full Text] [Related]
14. Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients.
Pirie-Shepherd SR; Painter C; Whalen P; Vizcarra P; Roy M; Qian J; Franks T; Coskran T; Golas J; Deng S; Zhong W; Tucker E; Marrinucci D; Gerber HP; Powell EL
PLoS One; 2017; 12(7):e0179561. PubMed ID: 28727782
[TBL] [Abstract][Full Text] [Related]
15. The zinc-finger transcriptional factor Slug transcriptionally downregulates ERα by recruiting lysine-specific demethylase 1 in human breast cancer.
Bai JW; Chen MN; Wei XL; Li YC; Lin HY; Chen M; Li JW; Du CW; Man K; Zhang GJ
Oncogenesis; 2017 May; 6(5):e330. PubMed ID: 28481366
[TBL] [Abstract][Full Text] [Related]
16. Prediction of years of life after diagnosis of breast cancer using omics and omic-by-treatment interactions.
González-Reymúndez A; de Los Campos G; Gutiérrez L; Lunt SY; Vazquez AI
Eur J Hum Genet; 2017 May; 25(5):538-544. PubMed ID: 28272536
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viruses: emerging options for the treatment of breast cancer.
Suryawanshi YR; Zhang T; Essani K
Med Oncol; 2017 Mar; 34(3):43. PubMed ID: 28185165
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive landscape of subtype-specific coding and non-coding RNA transcripts in breast cancer.
Vu TN; Pramana S; Calza S; Suo C; Lee D; Pawitan Y
Oncotarget; 2016 Oct; 7(42):68851-68863. PubMed ID: 27634900
[TBL] [Abstract][Full Text] [Related]
19. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
Lo WC; Li W; Jones EF; Newitt DC; Kornak J; Wilmes LJ; Esserman LJ; Hylton NM
PLoS One; 2016; 11(2):e0142047. PubMed ID: 26886725
[TBL] [Abstract][Full Text] [Related]
20. DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes.
Zhang M; Zhang S; Wen Y; Wang Y; Wei Y; Liu H; Zhang D; Su J; Wang F; Zhang Y
PLoS One; 2015; 10(11):e0142279. PubMed ID: 26550991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
